Form 4: Tyra Biosciences CEO Todd Harris Sells Shares Under 10b5-1 Trading Plan
SEC Form 4
Tyra Biosciences CEO Todd Harris sold shares of the company's common stock between September 18 and September 20, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Todd Harris, the President and CEO of Tyra Biosciences, sold shares of the company's common stock.
- The sales occurred on September 18, 19, and 20, 2024.
- The transactions were executed under a Rule 10b5-1 trading plan adopted in December 2022.
- On September 18, 2024, 3,500 shares were sold at $24 per share.
- On September 19, 2024, 5,671 shares were sold at a weighted average price of $24.3014, and 27 shares were sold at $25.0969.
- On September 20, 2024, 7,109 shares were sold at a weighted average price of $24.1877.
- Following these transactions, Todd Harris directly owns 1,489,620 shares of Tyra Biosciences common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, reporting stock sales by an executive. It is neutral in tone and factual in nature.
Risks
- Executive stock sales can sometimes be perceived negatively by investors, potentially impacting the stock price, although sales under a 10b5-1 plan are less likely to raise concerns.
Industry Context
Executive stock sales are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects. Sales under 10b5-1 plans are generally viewed as less informative since they are pre-arranged.
Stakeholder Impact
- Shareholders may react to the news of the CEO selling shares, although the existence of a 10b5-1 plan mitigates potential negative interpretations.
Key Dates
| Date | Description |
|---|---|
| December 2022 | Date the Reporting Person adopted a Rule 10b5-1 trading plan |
| 09/18/2024 | Date of first reported transaction: sale of 3,500 shares at $24 |
| 09/19/2024 | Date of second reported transaction: sale of 5,698 shares at weighted average price of $24.3014 and $25.0969 |
| 09/20/2024 | Date of third reported transaction: sale of 7,109 shares at weighted average price of $24.1877 |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.